S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

Chembio Diagnostics Stock Forecast, Price & News

+0.02 (+1.10%)
(As of 12/8/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
771,503 shs
Average Volume
5.53 million shs
Market Capitalization
$55.28 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Chembio Diagnostics logo

About Chembio Diagnostics

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases; handheld analyzers; and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Hauppauge, NY.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$32.47 million
Book Value
$1.59 per share


Net Income
$-25.52 million
Pretax Margin




Free Float
Market Cap
$55.28 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.48 out of 5 stars

Medical Sector

1085th out of 1,394 stocks

Pharmaceutical Preparations Industry

514th out of 674 stocks

Analyst Opinion: 3.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

Is Chembio Diagnostics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Chembio Diagnostics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CEMI, but not buy additional shares or sell existing shares.
View analyst ratings for Chembio Diagnostics
or view top-rated stocks.

How has Chembio Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Chembio Diagnostics' stock was trading at $3.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CEMI stock has decreased by 40.6% and is now trading at $1.84.
View which stocks have been most impacted by COVID-19

When is Chembio Diagnostics' next earnings date?

Chembio Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Chembio Diagnostics

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics, Inc. (NASDAQ:CEMI) released its earnings results on Thursday, November, 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.05. The firm had revenue of $12.06 million for the quarter. Chembio Diagnostics had a negative net margin of 72.24% and a negative trailing twelve-month return on equity of 86.50%. During the same quarter last year, the firm earned ($0.28) EPS.
View Chembio Diagnostics' earnings history

What price target have analysts set for CEMI?

1 analysts have issued 1 year target prices for Chembio Diagnostics' shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Chembio Diagnostics' share price to reach $8.00 in the next year. This suggests a possible upside of 334.8% from the stock's current price.
View analysts' price targets for Chembio Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the following people:
  • Richard L. Eberly, President, Chief Executive Officer, CFO & Director
  • Paul J. Angelico, Vice President-Operations
  • Javan Esfandiari, Chief Science & Technology Officer
  • Paul Lambotte, Vice President-Research & Development
  • Robert Passas, VP-International Sales & Business Development

What other stocks do shareholders of Chembio Diagnostics own?

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Segall Bryant & Hamill LLC (1.23%), BlackRock Inc. (0.93%), Geode Capital Management LLC (0.68%), Morgan Stanley (0.41%), Citadel Advisors LLC (0.00%) and Newbridge Financial Services Group Inc. (0.22%).
View institutional ownership trends for Chembio Diagnostics

Which institutional investors are selling Chembio Diagnostics stock?

CEMI stock was sold by a variety of institutional investors in the last quarter, including Segall Bryant & Hamill LLC, Millennium Management LLC, Squarepoint Ops LLC, and Newbridge Financial Services Group Inc..
View insider buying and selling activity for Chembio Diagnostics
or view top insider-selling stocks.

Which institutional investors are buying Chembio Diagnostics stock?

CEMI stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Geode Capital Management LLC, Citadel Advisors LLC, Jane Street Group LLC, Jump Financial LLC, Wolverine Trading LLC, and Signaturefd LLC.
View insider buying and selling activity for Chembio Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $1.84.

How much money does Chembio Diagnostics make?

Chembio Diagnostics has a market capitalization of $55.28 million and generates $32.47 million in revenue each year. The company earns $-25.52 million in net income (profit) each year or ($1.26) on an earnings per share basis.

How many employees does Chembio Diagnostics have?

Chembio Diagnostics employs 355 workers across the globe.

What is Chembio Diagnostics' official website?

The official website for Chembio Diagnostics is www.chembio.com.

Where are Chembio Diagnostics' headquarters?

Chembio Diagnostics is headquartered at 555 WIRELESS BLVD., HAUPPAUGE NY, 11788.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The company can be reached via phone at (631) 924-1135, via email at [email protected], or via fax at 631-924-2065.

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.